Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Your ultimate guide to the 2024 North Carolina State Fair
Recommended
North Carolina Voter Guide 2024: Who's running, how, where, when to vote in NC election
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xoma Corp 8.625%
(NQ:
XOMAP
)
26.30
+0.04 (+0.15%)
Streaming Delayed Price
Updated: 3:24 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,298
Open
26.41
Bid (Size)
26.24 (2)
Ask (Size)
26.50 (2)
Prev. Close
26.26
Today's Range
26.30 - 26.41
52wk Range
21.40 - 26.48
Shares Outstanding
N/A
Dividend Yield
8.20%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
September 23, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
September 23, 2024
From
XOMA Corporation
Via
GlobeNewswire
Performance
YTD
+2.14%
+2.14%
1 Month
+2.88%
+2.88%
3 Month
+3.46%
+3.46%
6 Month
+4.82%
+4.82%
1 Year
+15.55%
+15.55%
More News
Read More
XOMA Royalty to Present at Upcoming Investor Conferences in September
September 04, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
August 13, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
June 20, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
June 12, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
May 14, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
May 09, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
April 30, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Corporation Announces Closing of Tender Offer
April 03, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
March 21, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
March 19, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
March 08, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA to Present at Upcoming Investor Conferences in March
February 28, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
February 16, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
January 18, 2024
From
XOMA Corporation
Via
GlobeNewswire
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
January 11, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
January 08, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Announces Stock Repurchase Program of up to $50 Million
January 02, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
December 20, 2023
From
XOMA Corporation
Via
GlobeNewswire
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
December 19, 2023
From
XOMA Corporation
Via
GlobeNewswire
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
November 07, 2023
From
XOMA Corporation
Via
GlobeNewswire
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
October 31, 2023
From
XOMA Corporation
Via
GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
September 25, 2023
From
XOMA Corporation
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.